Karidium

Quick links to important sections

Karidium

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Karidium

Property Description
Active Ingredient Clobazam (INN)
Form Oral tablet (Solid dosage form)
Pharmacological Class Benzodiazepine / Anticonvulsant
General Purpose Stabilizing CNS overactivity, managing seizures, and anxiety
Origin Synthetic Compound

What Type of Medicine is Karidium (Clobazam)?

Karidium is a prescription-only psychotropic medicine defined by its active pharmaceutical ingredient, Clobazam, which belongs to the Benzodiazepine family of drugs. Specifically, it is classified as an Anticonvulsant (antiepileptic drug) due to its primary action in stabilizing nerve activity within the brain. This pharmacological role is characterized by the reduction of central nervous system hyperexcitability. Clobazam is primarily categorized as an antiepileptic agent intended to reduce excessive electrical discharge in the brain.

Composition, Origin, and Presentation

Karidium is a single-entity product, containing only the active substance Clobazam (INN) combined with an inert pharmaceutical excipient base. This medication is prepared as an oral solid dosage form, typically a tablet, intended for systemic absorption via oral administration. The synthetic origin of the compound ensures a consistent chemical structure (7-chloro-1-methyl-5-phenyl-1H-1,5-benzodiazepine-2,4(3H,5H)-dione), which is essential for maintaining predictable therapeutic action. Clobazam is distinguished by its 1,5-benzodiazepine structure, a feature less common than the 1,4-derivatives, influencing its profile when used as an adjunct therapy.

General Purpose and Functional Principle

The general purpose of Karidium is to act as a central nervous system depressant that establishes stability in brain function. Its functional principle involves acting as a positive allosteric modulator to enhance the effect of the brain's main inhibitory neurotransmitter, GABA (gamma-aminobutyric acid). By strengthening this natural calming signal, the drug provides a stabilizing effect that is generally leveraged to reduce the propensity for excessive nerve cell firing, thus providing a foundational benefit in managing states of neuronal overactivity, including both seizures and significant anxiety.

What side effects are possible with Karidium?

Possible Side Effects and Safety Information

The safety profile for Karidium, which contains the active ingredient sodium fluoride, is primarily characterized by the risk of toxicity following accidental ingestion, particularly in pediatric populations. While the product is intended for targeted use, consumption of amounts significantly higher than the recommended dose can lead to acute adverse events.

Adverse Reactions Scope

Adverse reactions associated with excessive exposure mainly involve the Gastrointestinal and Nervous Systems.

System-Organ Class Clinically Significant Adverse Reactions
Gastrointestinal Nausea, vomiting, diarrhea, abdominal pain, stomach cramps
Nervous System Lethargy, weakness, shaking, tremors

Serious reactions reported following accidental overdose can include severe gastrointestinal symptoms, difficulty breathing (dyspnea), and potential systemic effects that may require immediate medical attention. High or long-term ingestion of excessive amounts may also cause discoloration or pitting of developing teeth, a condition known as dental fluorosis, especially in children under six years of age.

Population-Specific Safety Considerations

  • Pediatric Population: The principal safety risk is acute toxicity from accidental ingestion in children, and the product is subject to regulatory measures addressing this risk. Certain formulations have exemptions from child-resistant packaging based on a maximum quantity of active ingredient deemed safe for accidental ingestion by a small child.
  • Overexposure: Long-term exposure to amounts above the recommended daily intake can potentially lead to skeletal fluorosis (deposit of fluoride in bones) or exacerbation of existing medical conditions like severe kidney problems or stomach ulcers.

Safety documents classify the base compound as toxic if swallowed, causing skin irritation and serious eye irritation. Therefore, the product must be stored out of the reach of children to mitigate the risk of accidental exposure.

Overdose and Emergency Response

Overdose and when to seek help

Karidium (Clobazam) overdose is primarily characterized by progressive Central Nervous System (CNS) depression. Initial documented manifestations include drowsiness, confusion, lethargy, dizziness, and motor impairments such as ataxia (lack of coordination) and slurred speech. These presentations reflect the drug’s potent effect as a CNS depressant.

The most severe, life-threatening outcomes involve the respiratory and circulatory systems. Regulatory documents indicate that overdose may progress to profound sedation, respiratory depression (slowed or shallow breathing), hypotension (low blood pressure), coma, and in rare cases, death. The risk of these severe outcomes is significantly elevated with the concomitant use of other CNS depressants, including alcohol and opioid medications. Furthermore, symptoms like drowsiness may be prolonged in older adults.

Immediate medical action is required when severe symptoms are observed. Any sign of unresponsiveness, loss of consciousness, or difficulty breathing mandates seeking emergency medical attention immediately. Overdose management, as officially described, is primarily symptomatic and supportive. This includes necessary procedures such as airway protection and continuous hemodynamic monitoring. Although the benzodiazepine antagonist Flumazenil is noted, its use in Clobazam toxicity is not well established due to the documented risk of precipitating acute withdrawal reactions.

Therapeutic Uses of Karidium

What Karidium Treats: Main Uses and Benefits

Karidium is generally utilized across two distinct therapeutic domains: it is applied where additional symptomatic support is needed in severe epilepsy syndromes and is considered relevant for short-term symptomatic relief for disabling anxiety. Its role is primarily focused on managing heightened, disruptive symptom patterns that interfere with daily stability and comfort.

This medication is used in combination with other treatments to help control seizures associated with Lennox-Gastaut syndrome. It is considered relevant as an adjunctive (add-on) therapy for certain complex seizure disorders, most notably Lennox-Gastaut syndrome (LGS) in patients aged two years and older. The medication is also relevant for the short-term, symptomatic management of severe anxiety and related agitation.

The therapeutic use is intended to provide symptomatic relief and supportive management during difficult episodes. This approach is directed toward maintaining a sense of stability when symptoms are more noticeable.


Quick Fact: Relief for Severe Symptom Patterns (Epilepsy & Anxiety)

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

This information is structured based on the official regulatory documentation for the medicine finerenone (brand name Kerendia), as no approved pharmaceutical drug is widely known by the name Karidium.

Populations Who Must Not Use (Contraindicated)

Classification Restriction
Absolute Conditions Patients with adrenal insufficiency or known hypersensitivity to any component of the medicine.
Drug Interactions Patients receiving concomitant treatment with strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin).

Conditional Eligibility and Restrictions

Classification Regulatory Statement (Limit/Exclusion)
Serum Potassium Treatment must not be initiated if the patient's serum potassium level is > 5.0 mEq/L (mmol/L).
Age Group Safety and effectiveness have not been established in pediatric patients (under 18 years of age).
Renal Function Use is not recommended in patients with severely impaired renal function ( eGFR < 25 mL/min/1.73 m^2).
Hepatic Function Avoid use in patients with severe hepatic impairment (Child-Pugh C).
Reproductive Status Breastfeeding is not recommended during treatment and for 1 day after the last dose. Use during pregnancy should be considered only if the benefit justifies the potential risk to the fetus.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Karidium (Clobazam) documents two main categories of interactions: pharmacodynamic effects leading to increased central nervous system (CNS) depression, and pharmacokinetic alterations involving metabolic enzymes.

Documented Pharmacodynamic Interactions

Co-administration with opioids and other CNS depressants (including antidepressants, antipsychotics, and sedatives) carries a specific regulatory warning due to the additive depressant effect. This combination increases the risk of profound sedation, respiratory depression, and coma, and is therefore subject to mandatory restrictions limiting dosage and duration of co-prescribing. Consumption of alcohol is also documented to potentiate CNS effects and increase Clobazam plasma concentrations by approximately 50%.

Documented Pharmacokinetic Interactions

  • Increased Exposure: Co-administration with strong or moderate CYP2C19 inhibitors (such as fluconazole, fluvoxamine, and omeprazole) results in a pharmacokinetic interaction that significantly increases the systemic exposure of the active metabolite, N-desmethylclobazam. This applies also to co-administration with Cannabidiol (CBD), which inhibits CYP2C19. Dosage adjustments are required under regulatory guidance when used with these inhibitors.
  • Reduced Clearance of Other Drugs: Karidium is documented as a weak inhibitor of CYP2D6, which reduces the clearance of other co-administered medicines that are substrates for this enzyme (e.g., dextromethorphan, pimozide, paroxetine). Dosage adjustment of the co-administered drug may be necessary.
  • Hormonal Contraceptives: The efficacy of hormonal contraceptives may be reduced. Nonhormonal birth control methods must be used during and for 28 days following the final dose, as officially stated in labeling.

Population-Specific Notes

Official labeling notes that patients with mild or moderate hepatic impairment have an increased susceptibility to adverse effects and interactions, requiring guidance for a reduced maximum dose.

Mechanism of Action

Targeting the Central Inhibitory Signaling Pathway

Karidium is a Positive Allosteric Modulator that engages the GABA A receptor complex, the primary site for inhibitory neurotransmission in the brain. Its mechanism is to enhance the functional effect of the body's natural inhibitory signal, gamma-aminobutyric acid (GABA), without activating the receptor directly. This targeted modulation achieves modulation of overactive or dysregulated neural processes, thereby resulting in a reduction of excessive signaling in key neural systems.


The Cascade from Molecular Interaction to Hyperpolarization

Binding to the receptor's allosteric site increases the frequency of chloride ion channel openings, leading to an amplified influx of negatively charged ions ( Cl^-) into the post-synaptic neuron. This molecular change initiates a rapid hyperpolarization of the cell membrane, which increases the threshold required for a neuron to fire an action potential. This physiological cascade modifies early molecular steps that shape systemic outcomes, ultimately resulting in the systemic stabilization of overactive neuronal responses across the central nervous system.


Subunit Selectivity and Functional Constraints

The drug exhibits affinity for GABA A receptors containing certain subunits (notably alpha2 over alpha1), which dictates specific differences in the resulting electrophysiological changes. However, the mechanism's efficacy is strictly GABA-dependent, and it is subject to the limitation of pharmacodynamic tolerance—the potential for the enhanced inhibitory effect to weaken over prolonged use due to adaptive changes within the receptor complex itself.

Dosage and Administration Information

The official instructions for the administration of Karidium (an ingestible sodium fluoride product) are defined by the medicine's regulatory status, as it belongs to a class of drugs that have not been formally reviewed and approved for safety, effectiveness, or quality since the 1940s.

Administration scope

Instruction Category Official Regulatory Status
Route of administration Not specified in approved labeling (Historically oral)
Dosing schedule Not applicable; no officially approved schedule exists
Timing in relation to meals Not applicable
Preparation requirements Not applicable
Age-group administration rules Regulatory intent targets labeling for children under 3 years of age
Missed-dose rules Not applicable
Special procedural conditions The product is an unapproved new drug subject to compliance action

Instruction Classifications

Classification Official Regulatory Basis
Administration method type Unapproved
Frequency pattern Unapproved
Regulatory basis Official regulatory classification for ingestible fluoride products
Use-context constraints Restricted to children aged 3 years and older who are at high risk for tooth decay

Resulting Procedural Structure

The regulatory status establishes the use protocol by defining the product's classification and the constraints on its sale:

  • Acknowledge Regulatory Status: The product is legally classified as an unapproved new drug.
  • Adhere to Use Restriction: Its use is intended to be limited to children aged 3 years and older who are at high risk for tooth decay.
  • Recognize Lack of Official Instructions: There are no official, standardized dosage and administration instructions published in an approved drug label or Summary of Product Characteristics (SmPC).

This official structure for the use of Karidium is defined by the regulatory and scientific position which restricts the product's marketing to a specific, high-risk pediatric population and legally prohibits its sale for use outside of that scope.

Recent Clinical Evidence

️ Karidium: Overview of Clinical Evidence

Evidence for use in Lennox-Gastaut Syndrome (LGS)

Research exploring how symptoms change over time for LGS was primarily evaluated in well-controlled Randomized Controlled Trials (RCTs). These short-term studies compared the compound administered alongside standard antiepileptic therapy to a placebo, including both pediatric patients (starting as young as 2 years old) and adults. Findings describe patterns observed in the studies regarding the weekly frequency of drop seizures and subsequent patient response rates. While the evidence structure is consistent for short-term research, long-term effects are mainly addressed by non-blinded Open-Label Extension (OLE) studies. Data show patterns related to the potential for the observed patterns of seizure frequency to diminish over years, and research is ongoing to contextualize this observation.


Evidence for use in Short-term Symptomatic Use in Severe Anxiety

Research where Karidium was studied for short-term symptomatic use in severe anxiety is derived from older Open-Label Trials and Comparative Studies. These trials used standardized anxiety rating scales to monitor changes in symptom scores over defined intervals, typically four to eight weeks. The evidence quality varies across studies for this indication, and certainty remains low compared to the LGS research. Follow-up durations were limited, meaning there is limited information for long-term follow-up scope for anxiety.


Long-term Studies and Research Gaps

For LGS, evidence is derived from extensive OLE studies that monitored outcomes related to episodic changes for multiple years. However, due to their observational nature, these long-term studies carry limitations, and effects are not fully established with the same certainty as the initial controlled trials. Research examined various age groups, but data for certain groups remain insufficient. For instance, high-quality evidence dedicated to research where the compound was studied solely for anxiety in children or older adults remains limited. Finally, comparative evidence is lacking from controlled trials that would directly contrast the compound against other relevant treatments, meaning the research does not determine whether an individual will respond similarly based on available data.

Key Studies & References NIH MedlinePlus Drug Information: Clobazam (Medication for Seizures and Anxiety)

Frequently Asked Questions (FAQ)

Common questions about Karidium (FAQ)

Q: What is Karidium used for besides the main condition?

Official product information states that Karidium (Clobazam) is indicated for two main purposes. It is used as an adjunctive (add-on) therapy for certain types of seizures and is also indicated for the short-term symptomatic treatment of severe anxiety.


Q: Can Karidium be taken by people with kidney issues?

According to official regulatory documents, caution is required when this medicine is used by patients with impaired kidney function. An adjustment to the initial dose and close monitoring may be necessary due to the potential for increased susceptibility to adverse effects.


Q: Are there any common foods or drinks that should be avoided when taking Karidium?

Official warnings state that consumption of alcohol should be avoided entirely. This combination significantly increases the risk of sedation and raises the level of the medicine in the body. However, taking Karidium with or without food does not affect how the medicine is absorbed.


Q: Is there a maximum amount of time someone can safely use Karidium?

For the symptomatic treatment of anxiety, regulatory documents recommend the course of treatment be short-term, usually not exceeding 8–12 weeks, including the period where the dose is reduced. Continuous long-term use, such as for seizure management, requires regular re-evaluation by a healthcare provider due to the documented risks of dependence and tolerance.


Q: Do studies suggest Karidium is effective for people of all ages?

Clinical research covers both adult and pediatric patients, generally those 3 years of age and older. However, official information indicates that special caution and closer monitoring are necessary when the medicine is used in children and older adults, and initial doses are often lower.


Q: What is the difference between Karidium and a dietary supplement?

Karidium is legally classified as a prescription-only psychotropic medicine, which means its use is strictly regulated by government agencies and requires a doctor's order. This designation, along with its classification as an anticonvulsant and a controlled substance, distinguishes it entirely from non-regulated dietary supplements.


Q: Is Karidium considered a 'strong' medicine?

Regulatory agencies classify Karidium as a controlled substance due to the potential risks of abuse, misuse, and dependence. Furthermore, the official product labeling includes warnings about the potential for serious adverse effects, which defines its highly regulated status.


Q: Can Karidium be split or crushed to make it easier to swallow?

Official product information indicates that some tablet forms of Karidium can be divided into two equal doses due to a score line on the tablet. Additionally, the tablets may be crushed and mixed with soft food, such as apple sauce, to help with administration. Patients should consult the specific patient information provided with the medicine.


Q: Is Karidium only for adults, or can teenagers take it?

Karidium is approved for use in adults and can also be used in pediatric patients, including adolescents and children over 3 years old. The appropriate use and dosage for this age group depend on the specific medical condition being addressed.


Q: Does taking Karidium require any special monitoring or regular blood tests?

Official guidance indicates that close monitoring for signs of dependence and for certain serious skin reactions, especially early in treatment, is necessary. Periodic blood tests may also be required to monitor the levels of other anti-seizure medicines that are being taken at the same time.


Q: What is the most serious potential interaction involving Karidium?

Official documents indicate that the most serious documented interaction is the co-administration with opioids and other medicines that depress the central nervous system (CNS). This combination significantly increases the risk of profound sedation, severe respiratory depression, and potentially coma or death.


Q: Are there any known interactions between Karidium and herbal remedies?

Yes, official information advises caution regarding herbal or over-the-counter products that can cause sedation or sleepiness. Taking these alongside Karidium may result in an enhanced depressant effect on the central nervous system.


Q: What were the main research findings that led to Karidium's approval?

Regulatory approval for use in Lennox-Gastaut Syndrome (LGS) was supported by controlled clinical trials. These studies demonstrated that when Karidium was added to standard anti-seizure therapy, it led to a significant reduction in the weekly frequency of drop seizures compared to a placebo.


Q: Does Karidium lose its effectiveness over time?

Official warnings note that the development of tolerance is a documented risk associated with Karidium, particularly during long-term use for seizures. Tolerance means that the body may adapt to the medicine, causing the enhanced inhibitory effect to potentially weaken over time.


Q: Why is Karidium not recommended for people with [specific medical history]?

Official documents list several contraindications, including pre-existing conditions like severe liver impairment, severe respiratory insufficiency, or muscle weakness such as myasthenia gravis. The medicine is not recommended in these cases because of the risk of the depressant effects worsening the underlying condition.


Q: Are there any special warnings for Karidium that I should be aware of?

Official regulatory labeling contains several important warnings, including the risks of abuse, dependence, and withdrawal. There are also specific warnings about the potential for severe skin reactions, such as Stevens-Johnson syndrome (SJS), and a documented risk of suicidal thoughts or behavior.


Q: How quickly should Karidium start working after I take it?

Regulatory information on the medicine's pharmacokinetics shows that it is absorbed relatively quickly into the bloodstream. The concentration of the medicine reaches its highest level in the blood between 30 minutes and 4 hours after a dose is taken.


Q: Is it okay for older adults to use Karidium?

Use of this medicine in older adults is possible, but they may be more susceptible to adverse effects like sedation, unsteadiness, and giddiness. For this reason, official guidance indicates that lower initial doses and careful observation are generally necessary.


Q: Does Karidium cause drowsiness or affect my ability to drive?

Drowsiness and sleepiness are documented as very common side effects of Karidium in official labeling. Due to the medicine's documented effect on coordination and thinking, official warnings exist regarding the performance of activities like driving or operating complex machinery.


Q: Can I stop taking Karidium suddenly, or do I need to taper off?

Official warnings state that abrupt discontinuation of Karidium should be avoided due to the significant risk of withdrawal symptoms and the potential for increased seizure frequency (rebound seizures). Therefore, the dose should be decreased gradually under a healthcare provider’s direction, as abrupt stopping is not recommended.


Q: Why is Karidium taken once a day, instead of multiple times?

Official posology guidelines indicate that a patient's total daily dose (up to 30 mg) may be taken as a single dose, typically administered at night. This is often done to help minimize the effects of daytime sleepiness. If the total daily dose is higher, it is usually divided into multiple smaller doses.


Q: Is Karidium available as a generic version?

Yes, the active substance Clobazam is approved for manufacture by multiple generic companies. Therefore, it is available as a generic oral tablet form.


Q: Is the side effect of dry mouth common with Karidium?

According to the list of documented adverse reactions, dry mouth is considered a common side effect of Karidium. This means it was reported in 1% to 10% of patients in clinical trials.


Q: Can Karidium make my skin more sensitive to the sun?

Official documentation indicates that photosensitivity reaction, which is an increased sensitivity to sunlight, has been reported with this medicine. However, the frequency of this specific reaction is not fully established in controlled clinical studies.


Q: Does Karidium interact with common over-the-counter pain relievers?

Official warnings highlight significant interactions with narcotic pain relievers, such as opioids, which can increase the risk of central nervous system (CNS) depression. The product labeling advises seeking guidance on the use of any non-narcotic over-the-counter pain relievers.


Q: Is Karidium safe to use during the summer months?

Regulatory storage instructions specify that the medicine must be protected from excessive heat and direct light. Given the reports of increased sun sensitivity (photosensitivity reaction), general sun protection practices may be helpful.


Q: Are there different strengths or doses of Karidium available?

Official product documentation confirms that the medicine is available in various strengths of oral tablets, such as 10 mg and 20 mg. It is also available in some regions as an oral suspension.


Q: Is Karidium addictive or habit-forming?

Yes, Karidium carries a documented risk of both physical and psychological dependence with repeated use, which is a major factor in its classification as a controlled substance by regulatory bodies. Patients should be aware of the potential for abuse and dependence.


Q: Is it normal to feel slightly dizzy when first starting Karidium?

Official information lists dizziness as a reported side effect. This is often associated with the medicine’s primary effects, such as impaired coordination and the common side effect of sleepiness that patients experience during treatment.


Q: What is the shelf life of Karidium?

The authorized shelf life for Karidium is determined during the regulatory approval process and is specific to each product formulation and strength. Official regulatory information indicates the product should not be used past the printed expiration date.


Q: How does Karidium fit into the larger treatment plan for my condition?

According to the official indications, Karidium has a defined role in a treatment plan. For managing seizures, it is indicated as an adjunctive (add-on) therapy. For treating severe anxiety, it is designated only for short-term symptomatic use.


Q: Why do some people feel no effect from Karidium?

Official regulatory information mentions that the medicine is metabolized by the liver, and the levels of its active metabolite can vary significantly between individuals due to genetic differences. This variation in metabolism may influence the medicine's effect from person to person.


Q: Is it mandatory to take Karidium with food?

Official pharmacokinetic studies indicate that it is not mandatory to take the medicine with food. Taking Karidium with or without food does not significantly change the total amount of the medicine that is absorbed into the body.


Q: Does Karidium show up on standard drug tests?

The active substance, Clobazam, is classified as a benzodiazepine and is processed by the body into an active metabolite. Official drug information indicates that this class of drug and its metabolites may be detectable in standard drug screening tests.


Q: How common are the severe side effects listed for Karidium?

Regulatory documents list the frequency of side effects based on clinical trial data. While minor side effects can be common, severe reactions like Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) are officially reported as very rare events.


Q: Does the color or shape of the Karidium pill matter?

Official regulatory documents describe the exact physical appearance, including the color, shape, and any markings, of the authorized tablets. This description is provided for the purpose of identification and quality control, ensuring patients have received the correct medicine.


Q: Can Karidium cause changes in appetite or weight?

Official safety documentation indicates that changes in appetite, including both decreased and increased appetite, are common side effects reported during clinical trials. Weight increase has also been reported as an uncommon side effect.


Q: What happens if I accidentally take two doses of Karidium at once?

Taking more than the prescribed amount can lead to symptoms of overdose, which include extreme drowsiness, confusion, and impaired coordination. Severe symptoms, such as slow, shallow breathing and coma, have been documented and necessitate prompt professional medical attention.


Q: Do experts view Karidium as a standard or specialized treatment?

The official indications for Karidium define its role as a specialized treatment. It is primarily indicated as an adjunctive (add-on) therapy for certain types of seizures and is restricted to short-term symptomatic use for severe anxiety.

How should Karidium be stored and disposed of?

Karidium (Clobazam) oral tablets must be stored according to regulatory requirements to ensure product integrity and secure handling.

Official Storage Conditions

The medicine is required to be stored at a controlled room temperature, specifically between 20 C and 25 C (68 F to 77 F). The product must be protected from freezing, excessive heat, moisture, and direct light. The tablets must be kept in their original, tightly closed container.

Security and Disposal Rules

As a controlled medicine, Karidium must be stored securely, out of the sight and reach of children, and pets. To dispose of unused or expired tablets, do not discard them in household trash or pour them down a drain or toilet. Instead, they must be returned to a pharmacist or an authorized drug take-back location for safe disposal according to local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Karidium found in:

A-Z Index: